MLH1 and endometrium neoplasm: In a study by Moore et al., immunohistochemistry was performed on 75 endometrial tumors comprising 25 cases with mutL homolog 1 (MLH1) promoter hypermethylation, 25 non-hypermethylated dMMR cases, and 25 pMMR cases to assess the expression of TIM-3 in the tumor and the microenvironment[81].